Internal and Emergency Medicine

, Volume 4, Issue 5, pp 381–388 | Cite as

Essential thrombocythemia: past and present

IM - Review

Abstract

Essential thrombocythemia (ET) is a clonal myeloproliferative disorder characterized by sustained increase in platelet number and tendency for thromboembolism. A somatic point mutation that causes a constitutive activation of the JAK2 gene is found in one in two ET patients. ET is more common in women, its incidence being 0.6–2.5/100,000 patient/year and the median age at diagnosis is 65–70 years. ET can affect all age groups, including children (0.09 cases/year), and is often diagnosed in the third–fourth decade of life. Rare cases of familial ET have been reported. Miscarriages are 3–4 times more common among women with ET than in the general population, especially in patients carrying JAK2V617F. Microvascular disturbances are typical of ET, but a major thrombosis (2/3 arterial and 1/3 venous; 1, 2–3% patient/year) is the main cause of morbidity and mortality. Age over 60 years and/or previous thrombosis are validated risk factor for thrombosis. Hemorrhages occur in 0.33% patient/year, mainly in those with a platelet count over 1,500 × 109/L. Progression to myelofibrosis and leukemia is more common in patients carrying the JAK2V617F mutation, and is estimated to occur in 0.16% and 0.12% patient/year, respectively. The ET-related mortality ratio with respect to the general population is 1:1, while for polycythemia vera it is 1.6:1. Low-dose aspirin is useful for microvascular disturbances, and in the primary and secondary prevention of major thrombosis in high-risk patients, but it is not recommended in patients with a platelet count over 1,500 × 109/L. Hydroxyurea is used as first-line treatment in high-risk patients. Other drugs available are alpha-interferon, anagrelide, pipobroman and busulphan.

Keywords

Thrombocythemia Myeloproliferative disorders Platelets JAK2 

References

  1. 1.
    Epstein E, Goedel A (1934) Hemorrhagische Thrombozythamie bei vascularer Schrumpfmilz (Hemorrhagic thrombocythemia with a vascular, sclerotic spleen). Virchows Archiv Pathos Anat Histopathol 293:233–248CrossRefGoogle Scholar
  2. 2.
    Fanger H, Lj CellaJr, Litchman H (1954) Thrombocythemia: report of three cases and review of literature. N Engl J Med 250:456–461PubMedCrossRefGoogle Scholar
  3. 3.
    Gunz FW (1960) Hemorrhagic thrombocythemia: a critical review. Blood 15:706–723PubMedGoogle Scholar
  4. 4.
    Ozer FL, Traux WE, Miesch DC et al (1960) Primary hemorrhagic thrombocythemia. Am J Med 28:807–823PubMedCrossRefGoogle Scholar
  5. 5.
    Dameshek W (1951) Some speculation on the myeloproliferative syndromes. Blood 6:372–375PubMedGoogle Scholar
  6. 6.
    Fialkow PJ, Faguet GB, Jacobson RJ et al (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in multipotent stem cell. Blood 58:916–919PubMedGoogle Scholar
  7. 7.
    Murphy S, Iland J, Rosenthal D et al (1986) Essential thrombocythemia: clinical and laboratory characteristics at presentation. Semin Hematol 23:177–192PubMedGoogle Scholar
  8. 8.
    Vardiman JW, Harris NL, Brunning RD (2002) The world health organization (WHO) classification of the myeloid neoplasms. Blood 14:2202–2292Google Scholar
  9. 9.
    Levine RL, Belisle C, Wadleigh M et al (2006) X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 107:4139–4141PubMedCrossRefGoogle Scholar
  10. 10.
    Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397PubMedCrossRefGoogle Scholar
  11. 11.
    Baxter EJ, Scott LM, Campbell PJ et al (2005) Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedGoogle Scholar
  12. 12.
    Kralovics R, Teo SS, Buser AS et al (2005) Altered gene expression in myeloproliferative disorders correlates with activation of signalling by the V617F mutation of Jak2. Blood 106:3374–3376PubMedCrossRefGoogle Scholar
  13. 13.
    James C, Ugo V, Le Couedic JP et al (2005) A unique clonal Jak2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144–1148PubMedCrossRefGoogle Scholar
  14. 14.
    Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788–22792PubMedCrossRefGoogle Scholar
  15. 15.
    Skoda R (2007) The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol 2007:1–10Google Scholar
  16. 16.
    Wolanskyj AP, Lasho TL, Schawager SM et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131:208–213PubMedCrossRefGoogle Scholar
  17. 17.
    Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 V617F mutation status: a prospective study. Lancet 366:1945–1953PubMedCrossRefGoogle Scholar
  18. 18.
    Johansson P (2006) Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemostas 32:171–173CrossRefGoogle Scholar
  19. 19.
    Randi ML, Putti MC, Scapin M et al (2007) Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 108:3600–3602CrossRefGoogle Scholar
  20. 20.
    Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–1097PubMedCrossRefGoogle Scholar
  21. 21.
    Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148–152PubMedGoogle Scholar
  22. 22.
    Wilkins BS, Erber WN, Bareford D et al (2007) Bone marrow pathology in essential thrombocythemia: intra-observer reliability and utility for identifying disease subtypes. Blood 111:60–70PubMedCrossRefGoogle Scholar
  23. 23.
    Elliott MA, Tefferi A (2005) Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Haematol 128:275–290PubMedCrossRefGoogle Scholar
  24. 24.
    Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 22:905–914PubMedCrossRefGoogle Scholar
  25. 25.
    Fabris F, Randi M, Casonato A et al (1980) Platelet aggregation and thrombopheresis in thrombocythemia. Thromb Haemostas 4:169Google Scholar
  26. 26.
    Carobbio A, Finazzi G, Guerini V et al (2007) Leucocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factor and JAK2 mutation status. Blood 109:2310–2313PubMedCrossRefGoogle Scholar
  27. 27.
    Falanga A, Marchetti M, Evangelista V et al (2000) Polymorphonuclear leucocytes activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96:4261–4266PubMedGoogle Scholar
  28. 28.
    Carobbio A, Finazzi G, Antonioli E et al (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112:3135–3137PubMedCrossRefGoogle Scholar
  29. 29.
    Harrison CN, Campbell RJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high risk essential thrombocythemia. N Engl J Med 353:33–45PubMedCrossRefGoogle Scholar
  30. 30.
    Vannucchi A, AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera and essential thrombocythemia. Blood 110:840–846Google Scholar
  31. 31.
    Barbui T, Barosi G, Grossi A et al (2004) Practice guidelines for the therapy of essential thrombocythemia. Haematologica 89:15–232Google Scholar
  32. 32.
    Cortelazzo S, Viero P, Finazzi G et al (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556–562PubMedGoogle Scholar
  33. 33.
    Kiladijan JJ, Cervantes F, Leebeek FWG et al (2008) The impact of Jak2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 111:4922–4929CrossRefGoogle Scholar
  34. 34.
    Randi ML, Rossi C, Barbone E et al (1994) Superior sagittal sinus thrombosis in 5 patients with essential thrombocythemia: a possible disease variant. Rev Iberoam Tromb Hemostasia 7:76–78Google Scholar
  35. 35.
    Federici A, Rand JH, Mannucci PM (2001) Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J 2:358–362PubMedCrossRefGoogle Scholar
  36. 36.
    Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–761Google Scholar
  37. 37.
    Hasle H (2000) Incidence of essential thrombocythemia in children. Br J Haematol 110:751PubMedCrossRefGoogle Scholar
  38. 38.
    Randi ML, Putti MC, Fabris F (2000) Features of essential thrombocythemia in childhood: study of five children. Br J Haematol 108:86–89PubMedCrossRefGoogle Scholar
  39. 39.
    Dror Y, Zipursky A, Blanchette VS (1999) Essential thrombocythemia in children. J Ped Hematol Oncol 21:356–363CrossRefGoogle Scholar
  40. 40.
    Randi ML, Putti MC, Pacquola E (2004) Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. Pediatr Blood Cancer 43:1–4CrossRefGoogle Scholar
  41. 41.
    Randi ML, Putti MC (2004) Essential thrombocythemia in children: is a treatment needed? Exp Opin Pharmacother 5:1009–1014CrossRefGoogle Scholar
  42. 42.
    Passamonti F, Ml Randi, Rumi E et al (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the Jak2 (617V>F) mutation. Blood 110:485–489PubMedCrossRefGoogle Scholar
  43. 43.
    Harrison C (2005) Essential thrombocythemia: challenges and evidence-based management. Br J Haematol 130:153–165PubMedCrossRefGoogle Scholar
  44. 44.
    Griesshammer M, Bangerter M, van Vliet HH (1997) Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemostas 23:371–377CrossRefGoogle Scholar
  45. 45.
    Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124PubMedCrossRefGoogle Scholar
  46. 46.
    Cortellazo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132–1136CrossRefGoogle Scholar
  47. 47.
    Randi ML, Ruzzon E, Tezza F (2005) Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 16:181–184PubMedCrossRefGoogle Scholar
  48. 48.
    Finazzi G, Ruggeri M, Rodeghiero F et al (2000) Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Haematol 110:577–583PubMedCrossRefGoogle Scholar
  49. 49.
    Passamonti F, Malabarba L, Orlandi E et al (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis. Br J Haematol 116:855–861PubMedCrossRefGoogle Scholar
  50. 50.
    Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51–54PubMedGoogle Scholar
  51. 51.
    Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863–866PubMedCrossRefGoogle Scholar
  52. 52.
    Barosi G, Besses C, Birgegard G et al (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21:277–280PubMedCrossRefGoogle Scholar
  53. 53.
    Barosi G, Birgegard G, Finazzi G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: results of a ELN consensus conference. Blood [e-pub ahead of print]Google Scholar
  54. 54.
    Apperley JF, Gardembas M, Melo JV et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:472–480CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Medical and Surgical SciencesUniversity of Padua Medical SchoolPaduaItaly

Personalised recommendations